Black Book Research, in its 2026 research series on payer IT, software, and services, reports that data usability, workflow activation, identity confidence, and provenance gaps, rather than transport alone, now define payer-to-payer interoperability success or failure.
Read More
Vadzo's Bolt-821CRS is a high-resolution 4K HDR MIPI CSI-2 camera module built on the Onsemi AR0821 HyperLux sensor, delivering embedded HDR exceeding 140 dB, direct SoC integration, and a compact board-level footprint purpose-built for UAV, robotics, medical, and edge AI platforms where USB overhead, power draw, and latency are system-level constraints.
Read More
Accomplished industrial technology sales executive - with senior leadership roles spanning Honeywell, Siemens, Armstrong Fluid Technology, and Johnson Controls - joins ECM to lead the next phase of global commercial growth
Read More
The major upgrade transforms passive note storage into active workflow automation, featuring a redesigned visual interface, seamless integrations, and frontier AI models to maximize professional efficiency.
Read MoreAutomated centralized compliance oversight designed to reduce vendor sprawl and eliminate manual tracking, mid-sized advisory firms find confidence in streamlined IAR CE management with A.D. Banker
Read MoreOndas Sentrycs' Cyber-over-RF Technology to Be Deployed Across Multiple FIFA World Cup Host Venues Across North America for Detection and Mitigation of Unauthorized Drones
Reinforces Sentrycs' Position as a Leading Provider of Non-Disruptive Counter-Drone Solutions for Large-Scale Civilian and Critical Infrastructure Environments
Read MoreNet revenue increase of 5% in Q4 2025 vs. Q3 2025
Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2 million due upon completion of post-closing conditions; and has received $3.0 of up to $20 million in milestone payments and other future payments
Agreement with Future Pak is fully aligned with Jaguar's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications moving forward
Jaguar will appeal Nasdaq's March 5, 2026 noncompliance determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026; delisting is stayed pending the panel's final decision
REMINDER: Friday, April 10, Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q4 2025 financials and company updates; Click here to register
Read More
